Granules India demonstrates a consistent annual earnings per share (EPS) growth rate of 4.5% over the past three years. Notably, insiders hold a significant 38% stake valued at approximately ₹69 billion, underscoring their commitment to upholding shareholder interests.

Granules India's financial year 2026 revenue increased by 20%, reaching INR 53,656 million. The peptide Contract Development and Manufacturing Organization (CDMO) business played a significant role in this growth, turning profitable in Q4, contributing INR 1,593 million to the company's positive EBITDA.

Granules India concluded its Q4 FY26 with a 14.2% year-over-year increase in net sales to INR 876.8 crore, and a 5.2% rise in net profit. EBITDA surged by 29.9%, reaching INR 191.4 crore. Shares have gained an impressive 54.6% over the past year, closing at INR 704.55.

Analysts from various brokerages are optimistic about the future of Sun Pharma, Dr Reddy's, Granules India, and Mankind Pharma, anticipating a potential increase of up to 21% in their share prices.

Granules India has released its Q4 financial results, highlighting crucial metrics for analysis.

Granules India has announced a dividend of INR 1.75 per share for Q4 FY26, following the completion of the Senn Chemicals buyout in FY26. Shareholders can expect this payment at the upcoming 35th AGM on August 6, 2026.

Granules saw a drop in their North American revenue share to 72% in Q4 FY26, compared to 79% in the same quarter of the previous fiscal year. This suggests a change in the company's revenue composition away from the North American region.

Granules India's Q2 earnings surge by 33%, reaching INR 201.5 crore, as revenue grows by 23% to INR 1470.6 crore. The company also saw a significant boost in EBITDA, up by 39.6%, with profit margins increasing year-on-year to 23.9%.

Granules India's fourth-quarter earnings increased significantly by 32%, reaching ₹2 billion compared to last year, indicating a robust financial performance. This marked an improvement over the previous year's Q4 net profit of ₹1.52B.

Granules India is set to release its Q4 results on April 29, with a particular emphasis on discussing factors affecting margins and pricing. Investors will be keen to learn about the company's performance and future outlook based on these critical elements.

Granules India will announce their financial results for the fiscal year 2026 during a board meeting on April 29, 2026, along with a decision on dividends. However, insider trading is currently restricted due to SEBI regulations until May 1, 2026.

Foreign Institutional Investors (FIIs) have shown a preference for small-cap stocks despite offloading ₹1.12T of Indian equities in March 2026, with notable investments in Shringar House of Mangalsutra, Granules India, Repco Home Finance, and Sharda Cropchem. The focus is driven by Shringar's projected 30% growth, Granules' new product launches, Repco's IT upgrades, and Sharda's robust global agrochemical market presence.

Granules India responds to FDA warnings by implementing increased supervision and a digital archiving system to address concerns about record-keeping and contamination at their main facility. With the U.S. being a significant revenue market, these measures are essential for maintaining compliance and regaining trust.

Granules India's Chantilly facility has successfully passed the US FDA's cGMP audit, despite four minor observations being made during the process. Fortunately, no data integrity concerns were identified in their operations.

Granules Life Sciences has received a Voluntary Action Indicated (VAI) status from the US FDA following an inspection, which focused on current Good Manufacturing Practices (cGMP) and pre-approval inspections. This classification does not suggest any regulatory action and allows for increased production capabilities at Granules Life Sciences.

Granules company reports that the recent FDA inspection resulted in a voluntary action classification. Following the inspection, the FDA decided not to take any additional regulatory actions.

Despite a minor decline during today's session, Granules India exhibits a positive outlook with strong moving averages and MACD indicators suggesting promising medium-term potential.